GlassScriptPhysician profile
Jefferson Moulds
NPI 1265420582
$3,575.97
in general payments reported to CMS, 2019-2025
51 companies · $84.95 in 2025
The $84.95 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $77.83 · 2022: $373 · 2023: $1,306 · 2024: $1,734 · 2025: $84.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,124.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $343.82 | 2022-2024 | Enhertu |
| Novartis Pharmaceuticals Corporation | $324.79 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $260.87 | 2023-2024 | Lynparza |
| Merck Sharp & Dohme LLC | $234.31 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $215.71 | 2023-2024 | Darzalex, Tecvayli, Talvey |
| Aveo Pharmaceuticals, INC. | $158.89 | 2023-2024 | Fotivda |
| Regeneron Healthcare Solutions, INC. | $133.99 | 2023-2024 | Libtayo |
| Myriad Genetic Laboratories, INC. | $123.43 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $105.89 | 2023-2024 | |
| Pharmaessentia USA Corporation | $104.37 | 2023-2024 | Besremi |
| Progenics Pharmaceuticals, INC. | $100.00 | 2022 | |
| Lilly USA, LLC | $96.84 | 2023-2024 | Jaypirca, Verzenio, Retevmo |
| Eisai INC. | $86.59 | 2023-2024 | |
| Foundation Medicine, INC. | $77.83 | 2020 | |
| Incyte Corporation | $76.58 | 2023-2024 | Jakafi, Pemazyre, Monjuvi |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $66.54 | 2024 | Brukinsa |
| Abbvie INC. | $62.75 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $57.51 | 2023 | Tazverik |
| Takeda Pharmaceuticals U.S.A., INC. | $50.90 | 2024 | Alunbrig, Fruzaqla |
| Exelixis INC. | $48.43 | 2023 | Cabometyx |
| Dendreon Pharmaceuticals LLC | $48.04 | 2023 | Provenge |
| Adc Therapeutics America, INC. | $45.83 | 2023-2024 | |
| Sobi, INC | $42.41 | 2024 | |
| Genentech USA, INC. | $41.11 | 2023 | Rozlytrek, Avastin, Gavreto |
| Boston Scientific Corporation | $40.67 | 2024 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Mirati Therapeutics, INC. | $39.62 | 2023 | Krazati |
| Puma Biotechnology, INC. | $39.01 | 2024 | |
| Seagen INC. | $37.03 | 2023 | Tivdak, Tukysa |
| Genmab U.S., INC. | $34.60 | 2023 | Epkinly |
| Glaxosmithkline, LLC. | $34.15 | 2024 | Jemperli, Zejula |
| Sumitomo Pharma America, INC. | $31.94 | 2024 | Orgovyx |
| Alnylam Pharmaceuticals INC. | $26.41 | 2023-2024 | Givlaari |
| Karyopharm Therapeutics INC. | $26.34 | 2024 | Xpovio |
| Immunogen, INC. | $25.15 | 2023 | Elahere |
| Blueprint Medicines Corporation | $24.80 | 2024 | Ayvakit |
| Genzyme Corporation | $24.64 | 2023 | |
| Spectrum Pharmaceuticals INC. | $23.07 | 2023 | Rolvedon |
| Agios Pharmaceuticals, INC. | $22.98 | 2024 | Pyrukynd |
| Pharmacosmos Therapeutics INC. | $22.41 | 2024 | Monoferric |
| E.R. Squibb & Sons, L.L.C. | $22.37 | 2023 | Opdivo |
| Astellas Pharma US INC | $21.09 | 2023 | Xospata |
| Pfizer INC. | $20.30 | 2024 | |
| Shield Therapeutics INC | $20.16 | 2024 | |
| Amgen INC. | $19.35 | 2023 | Vectibix, Xgeva, Nplate |
| Emd Serono, INC. | $17.89 | 2024 | |
| Array Biopharma INC | $17.72 | 2024 | Mektovi, Lorbrena, Braftovi |
| Siemens Medical Solutions USA, INC. | $17.11 | 2023 | Varian Identify, Halcyon |
| Acrotech Biopharma INC. | $17.07 | 2023 | Beleodaq |
| Recordati_rare_diseases_inc. | $15.74 | 2023 | Sylvant |
| Deciphera Pharmaceuticals INC. | $14.07 | 2024 | Qinlock |
| Janssen Pharmaceuticals, INC | $12.85 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jefferson Moulds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.